{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:39:24Z","timestamp":1781174364523,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T00:00:00Z","timestamp":1487808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX000596"],"award-info":[{"award-number":["BX000596"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK-64324"],"award-info":[{"award-number":["DK-64324"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11302-017-9555-6","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T04:20:50Z","timestamp":1487823650000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice"],"prefix":"10.1007","volume":"13","author":[{"given":"Yue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Peti-Peterdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna U.","family":"Brandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Riquier-Brison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel G.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa E.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Ecelbarger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellamkonda K.","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"9555_CR1","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1096\/fj.07-8807com","volume":"21","author":"T Rieg","year":"2007","unstructured":"Rieg T, Bundey RA, Chen Y, Deschens G, Junger W, Insel PA, Vallon V (2007) Mice lacking P2Y2 receptors have salt-resistant hypertension and facilitated renal Na+ and water reabsorption. FASEB J 21:3717\u20133726. doi:\n                    10.1096\/fj.07-8807com","journal-title":"FASEB J"},{"key":"9555_CR2","doi-asserted-by":"publisher","first-page":"F1715","DOI":"10.1152\/ajprenal.90311.2008","volume":"295","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Sands JM, Kohan DE, Nelson RD, Martin CF, Carlson NG, Kamerath CD, Ge Y, Klein JD, Kishore BK (2008) Potential role of purinergic signaling in urinary concentration in inner medulla: insights from P2Y2 receptor gene knockout mice. Am J Physiol Renal Physiol 295:F1715\u2013F1724. doi:\n                    10.1152\/ajprenal.90311.2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1681\/ASN.2007040443","volume":"19","author":"SS Wildman","year":"2008","unstructured":"Wildman SS, Marks J, Turner CM, Yew-booth L, Peppiat-Wildman CM, King BF, Shirley DG, Wang W, Unwin RJ (2008) Sodium-dependent regulation of renal amiloride-sensitive currents by apical P2 receptors. J Am Soc Nephrol 19:731\u2013742. doi:\n                    10.1681\/ASN.2007040443","journal-title":"J Am Soc Nephrol"},{"key":"9555_CR4","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1681\/ASN.2010040377","volume":"21","author":"JD Stockand","year":"2010","unstructured":"Stockand JD, Mironova E, Bugaj V, Rieg T, Insel PA, Vallon V, Peti-Peterdi J, Pochynyuk O (2010) Purinergic inhibition of ENaC produces aldosterone escape. J Am Soc Nephrol 21:1903\u20131911. doi:\n                    10.1681\/ASN.2010040377","journal-title":"J Am Soc Nephrol"},{"key":"9555_CR5","doi-asserted-by":"publisher","first-page":"F10","DOI":"10.1152\/ajprenal.00432.2007","volume":"294","author":"V Vallon","year":"2008","unstructured":"Vallon V (2008) P2 receptors in the regulation of renal transport mechanisms. Am J Physiol Renal Physiol 294:F10\u2013F27. doi:\n                    10.1152\/ajprenal.00432.2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11302-009-9151-5","volume":"5","author":"BK Kishore","year":"2009","unstructured":"Kishore BK, Nelson RD, Miller RL, Carlson NG, Kohan DE (2009) P2Y2 receptors and water transport in the kidney. Puriner Signal 5:491\u2013499. doi:\n                    10.1007\/s11302-009-9151-5","journal-title":"Puriner Signal"},{"key":"9555_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1146\/annurev-physiol-021909-135825","volume":"72","author":"H Pr\u00e6torius","year":"2010","unstructured":"Pr\u00e6torius H, Leipziger J (2010) Intrarenal purinergic signaling in the control or renal tubular transport. Annu Rev Physiol 72:377\u2013393. doi:\n                    10.1146\/annurev-physiol-021909-135825","journal-title":"Annu Rev Physiol"},{"key":"9555_CR8","doi-asserted-by":"publisher","first-page":"F463","DOI":"10.1152\/ajprenal.00236.2011","volume":"301","author":"V Vallon","year":"2011","unstructured":"Vallon V, Rieg T (2011) Regulation of renal transport mechanisms. Am J Physiol Renal Physiol 301:F463\u2013F475","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR9","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/MNH.0b013e3283487393","volume":"20","author":"J Leipziger","year":"2011","unstructured":"Leipziger J (2011) Luminal nucleotides are tonic inhibitors of renal tubular transport. Curr Opin Nephrol Hyperten 20:518\u2013522. doi:\n                    10.1097\/MNH.0b013e3283487393","journal-title":"Curr Opin Nephrol Hyperten"},{"key":"9555_CR10","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1681\/ASN.2014010118","volume":"26","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Peti-Peterdi J, M\u00fcller CE, Carlson NG, Baqi Y, Strasburg DL, Heiney KM, Villanueva K, Kohan DE, Kishore BK (2015) P2Y12 receptor localizes in the renal collecting duct and its blockade augments arginine vasopressin action and alleviates nephrogenic diabetes insipidus. J Am Soc Nephrol 26:2978\u20132987. doi:\n                    10.1681\/ASN.2014010118","journal-title":"J Am Soc Nephrol"},{"key":"9555_CR11","doi-asserted-by":"publisher","first-page":"F1194","DOI":"10.1152\/ajprenal.90774.2008","volume":"296","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Nelson RD, Carlson NG, Kamerath CD, Kohan DE, Kishore BK (2009) Potential role of purinerigic signaling in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 296:F1194\u2013F1201. doi:\n                    10.1152\/ajprenal.90774.2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrneph.2009.43","volume":"5","author":"JP Gr\u00fcnfeld","year":"2009","unstructured":"Gr\u00fcnfeld JP, Rossier BC (2009) Lithium nephrotoxicity revisited. Nat Rev Nephrol 5:270\u2013276. doi:\n                    10.1038\/nrneph.2009.43","journal-title":"Nat Rev Nephrol"},{"key":"9555_CR13","doi-asserted-by":"publisher","first-page":"F1139","DOI":"10.1152\/ajprenal.00718.2012","volume":"304","author":"BK Kishore","year":"2013","unstructured":"Kishore BK, Ecelbarger CM (2013) Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol 304:F1139\u2013F1149. doi:\n                    10.1152\/ajprenal.00718.2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR14","doi-asserted-by":"publisher","first-page":"F70","DOI":"10.1152\/ajprenal.00444.2011","volume":"302","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Pop IL, Carlson NG, Kishore BK (2012) Genetic deletion of the P2Y2 receptor offers significant resistance to development of lithium-induced polyuria accompanied by alterations in PGE2 signaling. Am J Physiol Renal Physiol 302:F70\u2013F77. doi:\n                    10.1152\/ajprenal.00444.2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR15","doi-asserted-by":"publisher","first-page":"F407","DOI":"10.1152\/ajprenal.00464.2012","volume":"305","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Li L, Kohan DE, Ecelbarger CM, Kishore BK (2013) Attenuation of lithium-induced natriuresis and kaliuresis in P2Y2 receptor knockout mice. Am J Physiol Renal Physiol 305:F407\u2013F416. doi:\n                    10.1152\/ajprenal.00464.2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11302-015-9469-0","volume":"11","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Peti-Peterdi J, Heiney KM, Riquier-Brison A, Carlson NG, M\u00fcller CE, Ecelbarger CM, Kishore BK (2015) Clopidogrel attenuates lithium-induced alterations in renal water and sodium channels\/transporters in mice. Puriner Signal 11:507\u2013518. doi:\n                    10.1007\/s11302-015-9469-0","journal-title":"Puriner Signal"},{"key":"9555_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","volume":"20","author":"K Sangkuhl","year":"2010","unstructured":"Sangkuhl K, Klein TE, Altman RB (2010) Clopidogrel pathway. Pharmacogenet Genomics 20:463\u2013465. doi:\n                    10.1097\/FPC.0b013e3283385420","journal-title":"Pharmacogenet Genomics"},{"key":"9555_CR18","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1073\/pnas.0510446103","volume":"103","author":"P Savi","year":"2006","unstructured":"Savi P, Zachayus J-L, Delesque-Touchard N, Labouret C, Herve C, Uzbiaga M-F, Pereillo J-M, Culouscou J-M, Bono F, Ferrara P, Herbert J-M (2006) The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 103:11069\u201311074. doi:\n                    10.1073\/pnas.0510446103","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9555_CR19","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","volume":"30","author":"L Wallentin","year":"2009","unstructured":"Wallentin L (2009) P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 30:1964\u20131977. doi:\n                    10.1093\/eurheartj\/ehp296","journal-title":"Eur Heart J"},{"key":"9555_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1517\/14656566.2011.550573","volume":"12","author":"MA Giorgi","year":"2011","unstructured":"Giorgi MA, Cohen Arazi H, Gonzalez CD, Di Girolamo G (2011) Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrel. Expert Opin Pharmacother 12:1285\u20131295. doi:\n                    10.1517\/14656566.2011.550573","journal-title":"Expert Opin Pharmacother"},{"key":"9555_CR21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","volume":"84","author":"P Savi","year":"2000","unstructured":"Savi P, Pereillo JM, Uzabiaga ME, Combalbert J, Picard C, Maffrand JP, Pascal M, Herbert JM (2000) Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84:891\u2013896","journal-title":"Thromb Haemost"},{"key":"9555_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ahj.2005.08.023","volume":"152","author":"JM Brophy","year":"2006","unstructured":"Brophy JM, Babapulle MN, Costa V, Rinfret S (2006) A Pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am Heart J 152:263\u2013269. doi:\n                    10.1016\/j.ahj.2005.08.023","journal-title":"Am Heart J"},{"key":"9555_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-3-642-29423-5_7","volume":"210","author":"I Berniochner","year":"2012","unstructured":"Berniochner I, Sibbing D (2012) Thienopyridine and other ADP-receptor antagonists. Handb Exp Pharmacol 210:165\u2013198. doi:\n                    10.1007\/978-3-642-29423-5_7","journal-title":"Handb Exp Pharmacol"},{"key":"9555_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/eurheartj\/ehm545","volume":"29","author":"L Wallentin","year":"2008","unstructured":"Wallentin L, Vaenhorst C, James S, Erlinge D, Braun \u00d6, Jakubowski JA, Sugidachi A, Winters KJ, Siebahn A (2008) Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29:21\u201330. doi:\n                    10.1093\/eurheartj\/ehm545","journal-title":"Eur Heart J"},{"key":"9555_CR25","doi-asserted-by":"crossref","unstructured":"Norgard NB, Abu-Fadel M (2009) Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag:873\u2013882","DOI":"10.2147\/VHRM.S5699"},{"key":"9555_CR26","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1124\/dmd.109.028498","volume":"17","author":"K Hagihara","year":"2009","unstructured":"Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T (2009) A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Met Disp 17:2145\u20132152. doi:\n                    10.1124\/dmd.109.028498","journal-title":"Drug Met Disp"},{"key":"9555_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2007","unstructured":"Reagan-Shaw S, Nihal M, Ahmad N (2007) Dose translation from animal to human studies revisited. FASEB J 22:659\u2013661. doi:\n                    10.1096\/fj.07-9574LSF","journal-title":"FASEB J"},{"key":"9555_CR28","doi-asserted-by":"publisher","first-page":"F1454","DOI":"10.1152\/ajprenal.00206.2011","volume":"303","author":"F Hanner","year":"2012","unstructured":"Hanner F, Lan L, Nguyen TX, Yu A, Peti-Peterdi J (2012) Intrarenal localization of the plasma membrane channel pannexin 1. Am J Physiol Renal Physiol 303:F1454\u2013F1459. doi:\n                    10.1152\/ajprenal.00206.2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1017\/S1092852900014681","volume":"11","author":"RJ Baldenssarini","year":"2006","unstructured":"Baldenssarini RJ, Pompili M, Tondo L (2006) Suicide in bipolar disorder: risks and management. CNS Spectr 11:465\u2013471","journal-title":"CNS Spectr"},{"key":"9555_CR30","doi-asserted-by":"publisher","first-page":"f3646","DOI":"10.1136\/bmj.f3646","volume":"346","author":"A Cipriani","year":"2013","unstructured":"Cipriani A, Hawton K, Stockton S, Geddes JR (2013) Lithium in the prevention of suicide in mood disorders: updated systemic review and meta-analysis. BMJ 346:f3646. doi:\n                    10.1136\/ bmj.f3646","journal-title":"BMJ"},{"key":"9555_CR31","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","volume":"381","author":"J Geddes","year":"2013","unstructured":"Geddes J, Miklowitz DJ (2013) Treatment of bipolar disorder. Lancet 381:1672\u20131682. doi:\n                    10.1016\/S0140-6736(13)60857-0","journal-title":"Lancet"},{"key":"9555_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399404008385","volume":"18","author":"MK Rowe","year":"2004","unstructured":"Rowe MK, Chuang DM (2004) Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev Mol Med 18:1\u201318. doi:\n                    10.1017\/S1462399404008385","journal-title":"Expert Rev Mol Med"},{"key":"9555_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1254\/jphs.CRJ05009X","volume":"99","author":"A Wade","year":"2005","unstructured":"Wade A, Yokoo H, Yanagita T, Kobayashi H (2005) Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J Pharmacol Sc 99:307\u2013321","journal-title":"J Pharmacol Sc"},{"key":"9555_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2165\/11599180-000000000-00000","volume":"29","author":"OV Florenza","year":"2012","unstructured":"Florenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF (2012) Does lithium prevent Alzheimer\u2019s disease? Drugs Aging 29:335\u2013342. doi:\n                    10.2165\/11599180-000000000-00000","journal-title":"Drugs Aging"},{"key":"9555_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1124\/pr.111.005512","volume":"65","author":"CT Chiu","year":"2013","unstructured":"Chiu CT, Want Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65:105\u2013142. doi:\n                    10.1124\/pr.111.005512","journal-title":"Pharmacol Rev"},{"key":"9555_CR36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1001\/archsurg.138.10.1055","volume":"138","author":"AE Luckey","year":"2003","unstructured":"Luckey AE, Parsa CJ (2003) Fluid and electrolytes in the aged. Arch Sug 138:1055\u20131060. doi:\n                    10.1001\/ archsurg.138.10.1055","journal-title":"Arch Sug"},{"key":"9555_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0891988712436690","volume":"25","author":"S Rej","year":"2012","unstructured":"Rej S, Herrmann N, Shulman K (2012) The effects of lithium on renal function in older adults\u2014a systematic review. J Geriatr Psychiatry Neurol 25:51\u201361. doi:\n                    10.1177\/0891988712436690","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"9555_CR38","doi-asserted-by":"publisher","first-page":"F812","DOI":"10.1152\/ajprenal.00554.2007","volume":"294","author":"JJ Bedford","year":"2008","unstructured":"Bedford JJ, Leader JP, Jing R, Walker LJ, Klein JD, Sands JM, Walker RJ (2008) Amiloride restores renal medullary osmolytes in lithium-induced nephrogenic diabetes insipidus. Am J Physiol Renal Physiol 294:F812\u2013F820. doi:\n                    10.1152\/ajprenal.00554.2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"9555_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/ki.2009.91","volume":"76","author":"ML Kortenoeven","year":"2009","unstructured":"Kortenoeven ML, Li Y, Shaw S, Gaeggeler HP, Rossier BC, Wetzels JF, Deen PM (2009) Amiloride blocks lithium entry through sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int 76:44\u201353. doi:\n                    10.1038\/ki.2009.91","journal-title":"Kidney Int"},{"key":"9555_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2165\/00003088-199529030-00004","volume":"29","author":"PR Finley","year":"1995","unstructured":"Finley PR, Warner D, Peabody CA (1995) Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 29:172\u2013191. doi:\n                    10.2165\/00003088-199529030-00004","journal-title":"Clin Pharmacokinet"},{"key":"9555_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev.pa.33.040193.002251","volume":"32","author":"MD Murray","year":"1993","unstructured":"Murray MD, Brater DC (1993) Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 32:435\u2013465. doi:\n                    10.1146\/annurev.pa.33.040193.002251","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9555_CR42","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.4088\/JCP.v64n1108","volume":"64","author":"KM Phelan","year":"2003","unstructured":"Phelan KM, Mosholder AD, Lu S (2003) Lithium interaction with the cyclooxygenase-2 inhibitors reofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry 64:1328\u20131334","journal-title":"J Clin Psychiatry"},{"key":"9555_CR43","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","volume":"32","author":"PG Conaghan","year":"2012","unstructured":"Conaghan PG (2012) A turbulent decade of NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int 32:1491\u20131502. doi:\n                    10.1007\/s00296-011-2263-6","journal-title":"Rheumatol Int"},{"key":"9555_CR44","first-page":"1220.5","volume":"30","author":"BK Kishore","year":"2016","unstructured":"Kishore BK, Brandes AU, Carlson NG, Zhang Y (2016) Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice (abstract). FASEB J 30:1220.5","journal-title":"FASEB J"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-017-9555-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11302-017-9555-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-017-9555-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T06:58:22Z","timestamp":1589439502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11302-017-9555-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,23]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["9555"],"URL":"https:\/\/doi.org\/10.1007\/s11302-017-9555-6","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,23]]},"assertion":[{"value":"13 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yue Zhang declares that s\/he has no conflict of interest.J\u00e1nos Peti-Peterdi declares that s\/he has no conflict of interest.Anna U. Brandes declares that s\/he has no conflict of interest.Anne Riquier-Brison declares that s\/he has no conflict of interest.Noel G. Carlson declares that s\/he has no conflict of interest.Christa E. M\u00fcller declares that s\/he has no conflict of interest.Carolyn M. Ecelbarger declares that s\/he has no conflict of interest.Bellamkonda K. Kishore declares that s\/he has no conflict of interest.Parts of this work were presented at the Experiment mal Biology 2016 meeting organized by FASEB, April 2016 in San Diego, CA, and appeared as a printed abstract in the proceedings of that meeting [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of the Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}